Literature DB >> 29450313

Anti-vascular endothelial growth factor indications in ocular disease.

Stefan Cornel1, Iliescu Daniela Adriana2, Timaru Cristina Mihaela1, Schmitzer Speranta2, De Simone Algerino1, Batras Mehdi1, Hosseini-Ramhormozi Jalaladin1.   

Abstract

The purpose of this systemic review was to investigate the indications of anti-vascular endothelial growth factor (anti-VEGF) in the treatment of ocular diseases. For this, a comprehensive literature research was performed exploring the current use of anti-VEGF in a variety of retinal or anterior segment diseases and highlighting the visual outcome for these patients. The anti-VEGF therapy is now commonly used for a wide range of pathologies like age-related macular degeneration, retinal vein occlusion or diabetic retinopathy. Pathological processes such as abnormal neovascularization, ocular angiogenesis and macular edema which can greatly reduce visual acuity are now targeted by anti-VEGF treatment, having a major impact on vision.

Entities:  

Keywords:  aflibercept; age-related macular degeneration; anti-VEGF therapy; bevacizumab; ranibizumab

Year:  2015        PMID: 29450313      PMCID: PMC5712945     

Source DB:  PubMed          Journal:  Rom J Ophthalmol        ISSN: 2457-4325


  51 in total

1.  Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion.

Authors:  Simone Donati; Paolo Barosi; Marco Bianchi; Muna Al Oum; Claudio Azzolini
Journal:  Eur J Ophthalmol       Date:  2012 Jul-Aug       Impact factor: 2.597

2.  Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.

Authors:  Michael Engelbert; Sandrine A Zweifel; K Bailey Freund
Journal:  Retina       Date:  2010-10       Impact factor: 4.256

3.  Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

4.  Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.

Authors: 
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

5.  Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma.

Authors:  John O Mason; Michael A Albert; Tarek O Persaud; Rachel S Vail
Journal:  Retina       Date:  2007-09       Impact factor: 4.256

6.  Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Authors:  Brandon G Busbee; Allen C Ho; David M Brown; Jeffrey S Heier; Ivan J Suñer; Zhengrong Li; Roman G Rubio; Phillip Lai
Journal:  Ophthalmology       Date:  2013-01-23       Impact factor: 12.079

Review 7.  Treatment of ocular metastasis with anti-VEGF: a literature review and case report.

Authors:  Haley Augustine; Monique Munro; Feisal Adatia; Marc Webster; Michael Fielden
Journal:  Can J Ophthalmol       Date:  2014-10       Impact factor: 1.882

8.  Hypoxic regulation of vascular endothelial growth factor in retinal cells.

Authors:  L P Aiello; J M Northrup; B A Keyt; H Takagi; M A Iwamoto
Journal:  Arch Ophthalmol       Date:  1995-12

Review 9.  Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.

Authors:  Amelie Pielen; Nicolas Feltgen; Christin Isserstedt; Josep Callizo; Bernd Junker; Christine Schmucker
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

Review 10.  Anti-VEGF Therapy and the Retina: An Update.

Authors:  Vikas Tah; Harry O Orlans; Jonathan Hyer; Edward Casswell; Nizar Din; Vishnu Sri Shanmuganathan; Louise Ramskold; Saruban Pasu
Journal:  J Ophthalmol       Date:  2015-08-31       Impact factor: 1.909

View more
  12 in total

1.  Proteomic analysis of anti-angiogenic effects by conbercept in the mice with oxygen induced retinopathy.

Authors:  Ji Jin; Lei Chen; Gao-Qin Liu; Pei-Rong Lu
Journal:  Int J Ophthalmol       Date:  2020-12-18       Impact factor: 1.779

2.  Response of Pediatric Choroidal Neovascularization to Anti-Vascular Endothelial Growth Factor.

Authors:  Sunil Ruparelia; Aishwarya Sundaram; Mishari Dahrab; Chris Symonds; Alan Cruess
Journal:  Cureus       Date:  2021-12-06

3.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

4.  Investigating the effects of carvacrol in rats using oxygen-induced retinopathy model.

Authors:  Abdulgani Kaymaz; Fatih Ulaş; Ayhan Çetinkaya; Sevilay Erimşah
Journal:  Indian J Ophthalmol       Date:  2021-05       Impact factor: 1.848

5.  Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study.

Authors:  Min Sagong; Se Joon Woo; Youkyung Lee
Journal:  Clin Ophthalmol       Date:  2021-05-11

6.  Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit.

Authors:  Bassey Fiebai; Victor Odogu
Journal:  Open Ophthalmol J       Date:  2017-10-31

7.  The Role of Deregulated MicroRNAs in Age-Related Macular Degeneration Pathology.

Authors:  Hanan ElShelmani; Michael A Wride; Tahira Saad; Sweta Rani; David J Kelly; David Keegan
Journal:  Transl Vis Sci Technol       Date:  2021-02-05       Impact factor: 3.283

8.  Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown.

Authors:  Manavi D Sindal; Kanika Chhabra; Vaibhav Khanna
Journal:  Indian J Ophthalmol       Date:  2021-03       Impact factor: 1.848

Review 9.  Age-Related Macular Degeneration: Role of Oxidative Stress and Blood Vessels.

Authors:  Yue Ruan; Subao Jiang; Adrian Gericke
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

10.  Impact of the COVID-19 pandemic's first wave on the care and treatment situation of intravitreal injections in a German metropolitan region.

Authors:  Birthe Stemplewitz; Joel Luethy; Ulrich Schaudig; Marc Schargus; Mau-Thek Eddy; Martin Spitzer; Ulrike Brocks; Julie Kieckhoefel; Christa Schneemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-10       Impact factor: 3.535

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.